Previous results from large population-based series of breast or ovarian cancer cases
| Age of diagnosis | All ovarian (Alsop et al 12) | Sporadic ovarian (Alsop et al 12) | Age of diagnosis | All TNT (Couch et al 13) | Sporadic TNT (Couch et al 13) | |
| Mutation | – | – | <35 | 34 | 18 | |
| Number tested | 156 | 91 | ||||
| % | 21.8 | 19.8 | ||||
| ≤40* | Mutation | 7 | 35–39 | 44 | 23 | |
| Number tested | 45 | 230 | 149 | |||
| % | 15.6 | 19.1 | 15.4 | |||
| 41–49 | Mutation | 37 | 40–49 | 47 | 18 | |
| Number tested | 153 | 368 | 209 | |||
| % | 24.2 | 12.8 | 8.6 | |||
| 51–60 | Mutation | 59 | 50–59 | 35 | 18 | |
| Number tested | 346 | 366 | 241 | |||
| % | 17.1 | 9.6 | 7.5 | |||
| 61+ | Mutation | 38 | 16 | 60+ | 12 | 6 |
| Number tested | 457 | 250 | 388 | 279 | ||
| % | 8.3 | 6.4* | 3.1 | 1.4 | ||
*Personal communication (Gillian Mitchell). By inference, as 62/749 with no ovarian cancer and no family history had a BRCA1/2 mutation, 46/499 (9.2%) of those aged ≤60 years had a mutation. Therefore, only sporadic high-grade serous ovarian cancer aged ≤60 years was likely to have breached the 10% threshold.
TNT, triple-negative tumour.